Ocuphire Pharma Inc
OCUP
Get informed when a big investor buys or sells
+ FollowMarket Cap$111.72M
Close$
Share Statistics
| Market cap | $111.72 Million |
|---|---|
| Enterprise Value | $57.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.8 |
| Beta | 0.31 |
| Outstanding Shares | 95,483,280 |
Return
| Return on Equity | 828.66% |
|---|---|
| Return on Assets | -115.75% |
| Return on Invested Capital | -48.87% |
Valuation & Multiples
| P/E Ratio | -3.66 |
|---|---|
| PEG | -40.07 |
| Price to Sales | - |
| Price to Book Ratio | -1.17 |
| Enterprise Value to Revenue | 11.28 |
| Enterprise Value to EBIT | -1.39 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.6 |
| Debt to Equity | -2.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 46,200▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.37%▲ 12.42% |
|---|---|
| Total Invested | $27.26M▼ 15.03% |
| Investors Holding | 60▲ 13.00% |
ESG Score
No data
About Ocuphire Pharma Inc
28 employees
CEO: Douglas Swirsky Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering...